Interní Med. 2007; 9(3): 124-128

Diuretics in the treatment of heart failure

doc. MUDr. Eva Goncalvesová CSc
Oddelenie zlyhávania a transplantácie srdca, Národný ústav srdcových a cievnych chorôb a.s., Bratislava

Retention of fluid with congestion, hypervolemia, and volume overload of heart are regular components of syndrome of advanced heart failure. The principle of the diuretic effect is the increase of urine formation as a consequence of the interference with transport mechanisms of chlorides, sodium, potassium and water on the level of tubuli and collecting ducts in kidneys. The article discusses pathophysiological and clinical consequences of congestion, strategies of diuretic therapy and its influence on morbidity and mortality of patients with heart failure.

Keywords: Key words: heart failure, congestion, diuretics, effective diuresis, mortality.

Published: April 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Goncalvesová E. Diuretics in the treatment of heart failure. Interní Med. 2007;9(3):124-128.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abraham WT, Shamshirsaz AA, Mcfann K, et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol, 2006; 47: 1615-1621. Go to original source... Go to PubMed...
    2. Adamson PB, Magalski A, Braunschweig F, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol, 2003; 41: 565-571. Go to original source... Go to PubMed...
    3. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J, 2006; 12: 1431-1439. Go to original source... Go to PubMed...
    4. Androne AS, Hryniewicz K, Hudaihed A, et al. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol, 2004; 10: 1254-1259. Go to original source... Go to PubMed...
    5. Annand IS, Florea, VG. Duiretics in chronic heart failure - benefits nad hazards. Eur Heart J, 2001; 3 (suppl G): G8-G18. Go to original source...
    6. Bennett T, Kjellstrom B, Taepke R, et al. Development of implantable devices for continuous ambulatory monitoring of central hemodynamic values in heart failure patients. Pacing Clin Electrophysiol, 2005; 6: 573-584. Go to original source... Go to PubMed...
    7. Brater DC. Diuretic therapy. N Engl J Med., 1998; 6: 387-395. Go to original source... Go to PubMed...
    8. Braunschweig F, Linde C, Eriksson MJ, et al. Continuous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure. Eur Heart J, 2002; 1: 59-69. Go to original source... Go to PubMed...
    9. Cleland JG, Swedberg K, Follath F, et al. Study group on diagnosis of the working group on heart failure of the european society of cardiology. The EuroHeart Failure survey programme- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 5: 442-463. Go to original source... Go to PubMed...
    10. Constant J. Pearls and pitfalls in the use and abuse of diuretics for chronic congestive heart failure. Cardiology, 1999; 3: 156-161. Go to original source... Go to PubMed...
    11. Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation, 1999; 12: 1311-1315. Go to original source... Go to PubMed...
    12. Cosin J, Diez J. Toric investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail., 2002; 4: 507-513. Go to original source... Go to PubMed...
    13. Davis BR, Piller LB, Cutler JA, et al. Antihypertensive and lipid-lowering treatment to prevent heart attack trial collaborative research group. Role of diuretics in the prevention of heart failure: the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation., 2006; 18: 2201-2210. Go to original source... Go to PubMed...
    14. Domanski M, Tian X, Haigney M, et al. Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail, 2006; 5: 327-332. Go to original source... Go to PubMed...
    15. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol, 2006; 12: 1759-1764. Go to original source... Go to PubMed...
    16. Faris R, Flather MD, Purcel H, et al. Diuretisc for heart failure. The cochrane database of systematic reviews 2006, Issue 1. Art.No.: CD0038, DOI: 10.1002/14651858.CD003838.pub2. Go to original source... Go to PubMed...
    17. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA, 2004; 16: 1963-1971. Go to original source... Go to PubMed...
    18. Gheorghiade M, Gottlieb SS, Udelson JE, et al. Tolvaptan investigators vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol, 2006; 7: 1064-1067. Go to original source... Go to PubMed...
    19. Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail., 2005; 4: 260-269. Go to original source... Go to PubMed...
    20. Gottlieb SS, Baruch L, Kukin ML, et al. Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol, 1990; 4: 827-831. Go to original source... Go to PubMed...
    21. Goncalvesová E, Lesný P, Luknár M, et al. Brain natriuretic peptide is powerful predictor of elevation of ventricular filling pressures in patients with advanced congestive heart failure. Europ Heart J 2003; 24 (abstr suppl): 532. Go to original source...
    22. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation., 2002; 11: 1348-1353. Go to original source... Go to PubMed...
    23. Gupta S, Neyses L. Diuretic usage in heart failure: a continuing conundrum in 2005. Eur Heart J, 2005; 7: 644-649. Go to original source... Go to PubMed...
    24. Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med, 1991; 3: 353-359. Go to original source... Go to PubMed...
    25. Chomsky DB, Lang CC, Rayos G, et al. Treatment of subclinical fluid retention in patients with symptomatic heart failure: effect on exercise performance. J Heart Lung Transplant, 1997; 8: 846-853.
    26. Joharchi MS, Neiser U, Lenschow U, et al. Thoratec left ventricular assist device for bridging to recovery in fulminant acute myocarditis. Ann Thorac Surg., 2002; 1: 234-235. Go to original source... Go to PubMed...
    27. Lisy O, Redfield MM, Jovanovic S, et al. Mechanical unloading versus neurohumoral stimulation on myocardial structure and endocrine function In vivo. Circulation, 2000; 3: 338-343. Go to original source... Go to PubMed...
    28. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestoin predicts good survival despite previous class IV symptoms of heart failure. Am Heart J, 2000; 6: 840-847. Go to original source... Go to PubMed...
    29. Mahdyoon H, Klein R, Eyler W, et al. Radiographic pulmonary congestion in end-stage congestive heart failure. Am J Cardiol, 1989; 9: 625-627. Go to original source... Go to PubMed...
    30. Murray MD, Haag KM, Black PK, et al. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy, 1997; 1: 98-106.
    31. Neuberg GW, Miller AB, O'connor CM, et al. Investigators: Diuretic resistance predicts mortality in patients with advanced heart failure. Prospective randomized amlodipine survival evaluation. Am Heart J, 2002; 1: 31-38. Go to original source... Go to PubMed...
    32. Packer M, Abraham WT, Mehra MR, et al. Prospective Evaluation and Identification of Cardiac Decompensation by ICG Test (PREDICT) Study Investigators and Coordinators. Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure. J Am Coll Cardiol, 2006; 11: 2245-2252. Go to original source... Go to PubMed...
    33. Podszus T, Wagner U, Ploch T. Clinical and haemodynamic effects of long-term treatment with torasemide in congestive heart failure. Cardiology, 1994: (Suppl 2): 124-130. Go to original source... Go to PubMed...
    34. Sanghi P, Uretsky BF, Schwarz ER. Vasopressin antagonism: a future treatment option in heart failure. Eur Heart J, 2005; 6: 538-543. Go to original source... Go to PubMed...
    35. Shah MR, Hasselblad V, Stinnett SS, et al. Dissociation between hemodynamic changes and symptom improvement in patient with advanced congestive heart failure. Eur J Heart Fail., 2002; 4: 297-304. Go to original source... Go to PubMed...
    36. Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol, 1998; 2 Pt 2: R263-279. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.